Feedback Share Discussion Threads

[sja123] 05/6/2015 12:05

For information....the Challenges in Endourology International meeting in Paris runs between 28-30 June 15....

Ben Turney, who ran the Oxford Stone trial evaluating TEXRad screening of kidney stones, which reported rapidly and with "promising" results, is speaking on Tuesday afternoon 30th June and has already submitted a paper with preliminary results of this trial for possible presentation at that time....

If the wider world of urology hadn't heard of TEXRad before....seems they will know all about it by the end of the month...

However, I would be surprised if we have to wait until end of June for any news at all given the rate of take up and interest around...

All IMO etc

[the stigologist] 05/6/2015 09:05

the ultra small round that fraudy took part in was simply designed to pump the share price i suspect

[sja123] 05/6/2015 09:05

No dump 65jack...hardly any trades compared to yesterday yet...just MMs playing with the price IMO...

[the stigologist] 05/6/2015 09:04

i bet the bucket shop clients have heard there is a placing coming

a BIG one at a big juicy discount so some of the less honest ones are forward selling

[65jack] 05/6/2015 09:02

this was pumped to high heaven on twitter hence the dump

[sja123] 05/6/2015 09:01

A little surprised by the low volume this morning....I had expected there to be a flurry of interest after yesterdays high volume...especially as you can now buy for virtually a full penny less than the highs of yesterday....

Be interesting to see how it pans out today....

[blueball] 05/6/2015 08:48

Small top up for me.

[blueball] 04/6/2015 14:44

hxxp://tradersown.co.uk/company/278409/Feedback-Plc

[andrbea] 04/6/2015 14:37

LSE again

seattle14:20

Share Prophets Good write up today saying this is a buy . That is why it went up . It is free to join

[sja123] 04/6/2015 13:42

Yes, LSE board quite active....also mentioned there that Oxford Stone results are to be presented at an endourology meeting in Paris this month, which perhaps went unnoticed at the end of the 11 May RNS........

"The research was led by Mr Ben Turney (Bernard Senior Clinical Researcher in Urology at the University of Oxford and Honorary Consultant Urological Surgeon) and carried out by Mr Daniel Stevens (Academic Clinical fellow in Urology at the University of Oxford)"

"Mr Ben Turney and team have further submitted their preliminary results as an abstract for a possible presentation to the Challenges in Endourology meeting ( in Paris in June 2015"

[andrbea] 04/6/2015 13:19

some LSe board posts today:

Veldt Can't help but think with directors buying 70k in 200k placing announced yesterday and then the share price article that the nomad is covering themselves.. Recent newsflow indicates the direction of the company

AwkwardTurtle 13:14

Jim Cheers mate- this has a lot going for it.. Mainly it's funded, trials/collaborations, solid BOD, great software, talks with majors and BOD own a lot like they did CARE (AVO) keeps them honest.

[sja123] 04/6/2015 13:13

Might be worth bearing in mind that the last time the company was requested to put out an RNS stating there was "no known reason for share price movement", they went on to make three or four further announcements in a couple of weeks, including deals in Korea, Brisbane, Texas and with Oxford Stone....

Just saying....it doesn't necessarily mean a jot.... and something is driving the volume here today IMO....

We'll see...but I'm quite happy to hold with what is already out there....

[sja123] 04/6/2015 11:20

No...still can't hear you Stig....this filter button is brilliant:-)

[the stigologist] 04/6/2015 10:44

beware of fraudy or bucket shop shills trying to pump this

[the stigologist] 04/6/2015 10:43

another placing imminent I suspect

[the stigologist] 04/6/2015 10:42

looks like they need mo money

[sja123] 04/6/2015 10:25

Great volume today and some resilience after the RNS....still buyers around...RNS better worded this time IMO...managed to get in the positive placing and director take up in that placing...

Nice to see a bit more activity anyway and might spark a bit more interest generally...

All IMO etc

[kenwrong] 04/6/2015 09:23

The company is already selling and making cash from the Texrad product. Add in the potential from deals this company has done against a market cap of £4m and I think investors are seeing the light.

[65jack] 04/6/2015 09:09

sold out for now. gl

[sja123] 04/6/2015 09:01

Very quiet here considering this morning's move....getting some traction now it would seem :-)

[hamidahamida] 04/6/2015 09:00

Breakout target 10p

[blueball] 03/6/2015 10:35

Edging higher after todays news.

[zeuss1] 03/6/2015 09:39

Feedback raise £200,000 for Texrad development, a modest raise considering the developments this year, which does suggest to me the company will be able to part self fund developments. The successful results of the kidney stone survey with Oxford Stone Group will see Feedback develop a TexRAD based kidney stone software product dedicated to the management of kidney stone patients. This is a huge market - see my earlier posts

7 billion people globally, of these 3-5% will get kidney stones, say 4% = 280 million. Of these, half will be treated by lithotripsy = 140 million cases Of which half is ineffective = 70 million cases. The average cost of Lithotripsy (£2k in the UK but $10k in the USA), say £3k. The total cost of wasted Lithotripsy = £21 billion, over an average life span so £21 billion divided by 70 would give value of world wasted market of around £300m pa.

[the stigologist] 28/5/2015 07:45

note SAR

NONRNS NONRNS Whack PLACING

[kenwrong] 26/5/2015 08:33

Thanks Lr2, podcasts and interviews also on their PR firms site too. hxxp://www.branduk.net/brand-stocks/feedback-fdbk/